Antiviral Immunoglobulin Market

Antiviral immunoglobulin sales will expand through 2036, with intravenous immunoglobulin holding 52.0% of the product type segment in 2026, driven by standardized treatment protocols and established clinical procurement patterns. The market is projected to reach USD 5.5 billion in 2026 and USD 10.08 billion by 2036, creating an incremental opportunity of USD 4.56 billion.